195 West Street
About PAREXEL International
THE CLEAREST PATH TO CAREER FULFILLMENT STARTS WITH PAREXEL.
At PAREXEL, the best minds in the industry are simplifying the journey from science to new treatments—and getting them into the hands of those who need them most. If you join us, you can be a part of that. Through innovative processes and technology, your journey with us will not only be challenging but truly rewarding. PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.
PAREXEL Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates approximately 75 locations in over 50 countries around the world, and has more than 15,000 employees. For more information about PAREXEL International, visit www.PAREXEL.com.
480 articles with PAREXEL International
PAREXEL Ranked #1 Among Global CROs for Leadership in Phase II/III Clinical Research in Prominent Annual ISR CRO Quality Benchmark Survey
Company recognized for service provider leadership among global customers
3/15/2019Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more.
Additions support increased demand and complexity in oncology drug development and commercialization
2/15/2019Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.
The new additions join more than 60 former global regulators in the group and will be focused on helping companies understand and work within the current FDA and global regulatory climates to optimize drug development and mitigate risk of unnecessary delays.
Company has once again been recognized for its diverse and flexible workplace by Forbes and FlexJobs.
PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively
PAREXEL International Corporation today introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.
Recognitions include first-ever Scrip Award for Best Use of Real-World Evidence and “Best in Show” Fierce Innovation Award for partnership with Datavant, as FDA issues framework highlighting potential of RWE to industry
Josef von Rickenbach will step down as Chairman of the Board of Directors effective December 31, 2018.
The program will bring high-value training opportunities to China’s clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China’s biopharmaceutical industry.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Today announced the appointment of new members to the Board of Directors following Pamplona Capital Management’s acquisition in September 2017.
PAREXEL Navigates China’s Complex Drug Development and Market Landscape for Global Biopharmaceutical Companies with New China Advisory Service
The offering leverages PAREXEL’s deep experience with and knowledge of the Chinese biopharmaceutical landscape to help companies navigate all aspects of the country’s drug development process.
Solutions Built on the Perceptive Cloud Platform Leverage Mobile and Wearable Technology
PAREXEL Advances Patient-Centric Drug Development with Introduction of Its Patient Innovation Center
The Center can help sponsors improve the drug development process by reducing the practical, financial and geographical barriers patients and caregivers often face, and optimize patient involvement and engagement.
PAREXEL International Corporation announced that Xavier Flinois, President of PAREXEL Informatics, has been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
PAREXEL to Lead Discussions on Global Drug Development, Unveil New Industry Research at DIA Annual Meeting
PAREXEL International Corporation announced today that several of its experts will discuss key issues facing the industry at the 54th Drug Information Association (DIA) Annual Meeting
PAREXEL International Corporation announced that the Company has received recognition for its service and expertise from several notable industry organizations.
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company's Board of Directors effective May 1, 2018.